Tag Archives: China

R&D Trends for 2013: Data Trims, Partnerships, and Emerging Global Players

The Tufts Center for the Study of Drug Development (CSDD) sees two key trends as increasingly important for pharmaceutical companies to maintain success: eliminating the bane of extraneous data and fostering collaborations with academia and multi-company consortia both as measures of reducing costs and remaining competitive by more quickly and effectively guiding medicines to market. […]
Posted in Emerging Markets, IP, R&D, Strategy | Also tagged , | 1 Comment

Pharma's Reputation: A Boost in the US, but China Strikes a Sour Note

The pharmaceutical industry’s global reputation is on the mend, even if some countries – notably China – are more hostile, according to the latest Ipsos Reputation Snapshot for the Pharmaceutical Sector, from the Ipsos Global Reputation Centre. Since the last Ipsos survey in 2008, pharma’s reputation has improved significantly in the US, more so than […]
Posted in Corporate Responsibility, Emerging Markets, Safety, Strategy | Tagged | Leave a comment

SciClone Pharmaceuticals: Selling Specialty Drugs in China

US-based SciClone Pharmaceuticals has built its business around selling specialty drugs in China. Companies like Sanofi and Pfizer, despite their own in-country resources, have partnered with SciClone and are achieving better returns, according to SciClone CEO Friedhelm Blobel.
Posted in Biotech, compliance, Emerging Markets, Global, healthcare, IP, Legal, Manufacturing, People, pricing, Regulatory, Sales, Strategy | Also tagged , | 1 Comment

Tasty Asian Acquisition for Publicis

Publicis Healthcare Gobbles Up Another Asian Agency Publicis continues its expansion into Asia with today’s (Feb 20) announcement of its acquisition of U-Link Business Solutions (UBS), one of China’s leading agencies specializing in healthcare communications. As a part of Publicis Healthcare Communications Group, the agency will be renamed UBS Saatchi & Saatchi Health. “The Chinese […]
Posted in Agency Insight, Emerging Markets, Global, Guest Blog | Also tagged , , , | Leave a comment

California Life Sciences to Partner with China

BIOCOM, a trade group representing Southern California’s life sciences industry, is ramping up partnership efforts in China to meet an emerging desire for novel drug therapies. While intellectual property (IP) protections and the Chinese government’s willingness to pay for expensive new products represent two large and lingering question marks, Joe Panetta, president and CEO at […]
Posted in Biotech, Emerging Markets, Global, IP, leadership, Market Access, R&D | Also tagged , , , | Leave a comment
  • Categories

  • Meta